FDA approves generic version of acne treatment

July 3, 2012

FDA has approved Perrigo Company’s abbreviated new drug application for a generic version of clindamycin phosphate and benzoyl peroxide 1.2%/5% gel (Duac Gel, Stiefel Laboratories), the company recently announced in a statement. The gel is indicated for the topical treatment of inflammatory acne vulgaris.

FDA has approved Perrigo Company’s abbreviated new drug application for a generic version of clindamycin phosphate and benzoyl peroxide 1.2%/5% gel (Duac Gel, Stiefel Laboratories), the company recently announced in a statement. The gel is indicated for the topical treatment of inflammatory acne vulgaris.

Photo courtesy of Perrigo Company

“We’re pleased to bring this new topical product to market and continue to focus on our mission of making healthcare more accessible and affordable for consumers,” said Joseph C. Papa, Perrigo’s chairman, president, and CEO.

The company has begun shipment of the gel.

This treatment is contraindicated in people with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.